Deferasirox in MDS patients with transfusion-caused iron overload—a phase-II study

References

Page 1

	Year	Citations
World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues D. K. Hossfeld Annals of Oncology Hematological MalignancyLymphoid NeoplasiaTumoral PathologyLymphoid TissuesCancer Pathology	2002	4.6K
MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients John C. Wood, Cathleen Enriquez, Nilesh R. Ghugre, Blood	2005	1K
Pathology and genetics: Tumours of haematopoietic and lymphoid tissues Paresh Vyas The Lancet Oncology Lymphoid NeoplasiaCancer PathologyHematologyHistopathologyPathology	2001	988
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia Maria Domenica Cappellini Blood	2005	713
Non-invasive assessment of hepatic iron stores by MRI Y. Gandon, Damien Olivié, Dominique Guyader, The Lancet Hepatic Iron StoresEngineeringHepatologyMedical ImagingPet-mri	2004	665
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis Dudley J. Pennell Blood	2005	482
A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Mark Tanner, R. Galanello, C. Dessì, Circulation	2007	470
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial Eric Nisbet‐Brown, Nancy F. Olivieri, Patricia J. Giardina, The Lancet Iron-loaded PatientsIron MetabolismHematologyClinical TrialsPatient Safety	2003	330
A randomised comparison of deferasirox<i>versus</i>deferoxamine for the treatment of transfusional iron overload in sickle cell disease Elliott Vichinsky, Onyinye Onyekwere, John B. Porter, British Journal of Haematology	2006	270
Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia Major Lawrence C. Wolfe, Nancy F. Olivieri, Darlene Sallan, New England Journal of Medicine Heart FailurePharmacotherapyCardiovascular ToxicityIron DeficiencyAcute Myocardial Infarction	1985	270

Page 1